Episode 5- Subcutaneous neostigmine for Ogilvie's Syndrome

05/15/20 • 10 min

In this episode, we look into the pharmacological treatment of Ogilvie's Syndrome using subcutaneous neostigmine. Please remember to subscribe to our podcast and leave us feedback!
References:
Lopez Valle RG, Godoy FL. Neostigmine for acute colonic pseudo-obstruction: a meta-analysis. Annals of Medicine and Surgery. 2014; 3: 60-64

Bernardi MP, et al. Acute and chronic pseudo-obstruction: a current update. ANZ J Surg. 2015; 85: 709-714

Vogel JD, et al. Clinical practice guidelines for colon volvulus and acute colonic pseudo-obstruction. Dis Colon Rectum. 2016; 59: 589-600

Kram B, et al. Efficacy and safety of subcutaneous neostigmine for ileus, acute colonic pseudo-obstruction, or refractory constipation. Annals of Pharmacotherapy. 2018; 52(6): 505-512.

Frankel, et al. Subcutaneous neostigmine appears safe and effective for acute colonic pseudo-obstruction. ANZ J Surg; 2019: https://doi.org/10.1111/ans.15265

Naveed M, et al. American society for gastrointestinal endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus. Gastrointest Endosc. 2020; 91: 228-235

Sgouros SN, et al. Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial. Gut; 2006: 55: 638–42

Neostigmine. In UpToDate. Waltham, MA.: UpToDate; 2020. www.uptodate.com. Accessed May 14, 2020.
Disclaimer:
The information contained within the ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution, seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on beha

Support the show

Find ER-Rx:
- On Instagram: @ERRxPodcast
- On the website: errxpodcast.com
- On YouTube
Disclaimer:

The information contained within the ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution, seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of, any medical institutions, educational facilities, or other healthcare programs.

Bernardi MP, et al. Acute and chronic pseudo-obstruction: a current update. ANZ J Surg. 2015; 85: 709-714

Vogel JD, et al. Clinical practice guidelines for colon volvulus and acute colonic pseudo-obstruction. Dis Colon Rectum. 2016; 59: 589-600

Kram B, et al. Efficacy and safety of subcutaneous neostigmine for ileus, acute colonic pseudo-obstruction, or refractory constipation. Annals of Pharmacotherapy. 2018; 52(6): 505-512.

Frankel, et al. Subcutaneous neostigmine appears safe and effective for acute colonic pseudo-obstruction. ANZ J Surg; 2019: https://doi.org/10.1111/ans.15265

Support the show

Previous Episode

Episode 4- Guidelines on the acute treatment of cerebral edema

In this episode, we discuss hypertonic saline solutions and mannitol for the treatment of cerebral edema in a variety of clinical settings. Please remember to subscribe to our podcast and leave us a comment to enter a drawing for your chance to win a gift!
References:
Cook, AM, et al. Guidelines for the acute treatment of cerebral edema in neurocritical care patients. Neurocrit care. 2020. https://doi.org/10.1007/s12028-020-00959-7

Mesghali E, at al. Safety of peripheral line administration of 3% hypertonic saline and mannitol in the emergency department. J Emerg Med. 2019; 4: 431-436

Perez, CA, et al. Complication rates of 3% hypertonic saline infusion through peripheral intravenous access. J Neurosci Nurs. 2017; 49(3): 191-195

Mannitol [prescribing information] Lake Forest, IL: Hospira; 2019
Disclaimer:
The information contained within the ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution, seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of, any medical institutions, educational facilities, or other healthcare programs.

Support the show

Next Episode

Episode 6- Can we use corticosteroids to reduce reintubation rates?

In this episode, we discuss the use of prophylactic corticosteroids for patients at high risk of reintubation. Please leave us a comment for your chance to win a medically-related prize!
References:
Kuriyama A, et al. Prophylactic corticosteroids for prevention of postextubation stridor and reintubation in adults: a systematic review and meta analysis. CHEST. 2017; 151(5): 1002-1010

Girard TD, et al. An official American Thoracic Society/ American College of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. Am J Respir Crit Care Med. 2017; 195(1): 120-133
Disclaimer:
The information contained within the ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution, seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of, any medical institutions, educational facilities, or other healthcare programs.

Support the show

ER-Rx: An ER + ICU Podcast - Episode 5- Subcutaneous neostigmine for Ogilvie's Syndrome

Transcript

Adis00:00:12.000

Hello everyone, and welcome to Episode 5 of ER-Rx. In today's episode, we are going to discuss Ogilvie's Syndrome, otherwise known as acute colonic pseudo-obstruction, as well as its treatment with subcutaneous neostigmine. First of all, what is Ogilvie's Syndrome? Ogilvie's Syndrome is defined as massive colonic dilation with signs and symptoms of colonic obstruction, but without overt mechanical blockage seen on imaging. Although it is still a very